[1]方主亭,张 雯,马婧嵚,等.血管内近程放疗在肝癌合并门静脉一级分支癌栓中的应用[J].介入放射学杂志,2021,30(01):74-78.
　FANG Zhuting,ZHANG Wen,MA Jinqin,et al.Application of endovascular brachytherapy combined with transcatheter arterial chemoembolization in treating hepatocellular carcinoma associated with tumor thrombus in the first- order branch of portal vein[J].journal interventional radiology,2021,30(01):74-78.
点击复制

血管内近程放疗在肝癌合并门静脉一级分支癌栓中的应用()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
30
期数:
2021年01
页码:
74-78
栏目:
临床研究
出版日期:
2021-01-25

文章信息/Info

Title:
Application of endovascular brachytherapy combined with transcatheter arterial chemoembolization in treating hepatocellular carcinoma associated with tumor thrombus in the first- order branch of portal vein
作者:
方主亭;  张 雯;  马婧嵚;  刘清欣;  罗剑钧;  颜志平
Author(s):
FANG Zhuting;  ZHANG Wen;  MA Jinqin;  LIU Qingxin;  LUO Jianjun;  YAN Zhiping.
Department of Vascular and tumor Intervention， Fujian Provincial Hospital，Provincial Clinlcal Medical College of Fujian Medical University， Fuzhou， Fujian Province，350001， China
关键词:
【关键词】 肝细胞肝癌;  门静脉一级分支癌栓;  碘-125粒子条; 经动脉化疗栓塞术
文献标志码:
A
摘要:
【摘要】 目的 评估碘-125（125I）粒子条联合动脉化疗栓塞（TACE）治疗肝细胞肝癌（HCC）合并门静脉一级分支癌栓的安全性及有效性。 方法 回顾性分析2013年1月至2018年1月就诊的71例HCC合并门静脉一级分支癌栓患者的病历资料，24例接受门静脉一级分支125I粒子条植入术联合TACE术作为研究组，47例仅接受TACE术作为对照组。对比分析两组患者的基本资料、生存时间及不良事件的发生率。结果 研究组24例患者均成功接受门静脉一级分支植入125I粒子条。两组患者平均随访时间（11.7±7.5）个月，研究组和对照组的中位生存时间分别为（24.0±4.0）和（10.7±0.7）个月（P＜0.001）。两组患者接受相应治疗后均未出现严重相关不良事件。结论 125I粒子条联合TACE治疗HCC合并门静脉一级分支癌栓不仅安全而且明显延长了患者的生存时间。

参考文献/References:

［1］ Torre LA， Bray F， Siegel RL， et al. Global cancer statistics， 2012［J］. CA Cancer J Clin， 2015， 65： 87-108.
［2］ Ohnishi K， Okuda K， Ohtsuki T， et al. Formation of hilar collaterals or cavernous transformation after portal vein obstruc-tion by hepatocellular carcinoma［J］. Gastroenterology， 1984， 87： 1150-1153.
［3］ Ikai I， Hatano E， Hasegawa S， et al. Prognostic index for patients with hepatocellular carcinoma combined with tumor thrombosis in the major portal vein［J］. J Am Coll Surg， 2006， 202： 431-438.
［4］ Wu CC， Hsieh SR， Chen JT， et al. An appraisal of liver and portal vein resection for hepatocellular carcinoma with tumor thrombi extending to portal bifurcation［J］. Arch Surg， 2000， 135： 1273-1279.
［5］ Cheng AL， Kang YK， Chen Z， et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma：a phase Ⅲ randomized，double-blind，placebo-controlled trial［J］. Lancet Oncol， 2009， 10： 25-34.
［6］ Llovet JM， Ricci S， Mazzaferro V， et al. Sorafenib in advanced hepatocellular carcinoma［J］. N Engl J Med， 2008， 359： 378-390.
［7］ Luo J， Guo RP， Lai EC， et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis： a prospective comparative study［J］. Ann Surg Oncol， 2011， 18： 413-420.
［8］ Georgiades CS， Hong K， D’angelo M， et al. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis［J］. J Vasc Interv Radiol， 2005， 16： 1653-1659.
［9］ 张子寒，罗剑钧，颜志平，等． 血管内近程放疗联合支架植入及经动脉化疗栓塞治疗肝细胞肝癌合并门脉主干癌栓［J］． 复旦学报（医学版）， 2016， 43：1-8．
［10］ 周永杰，马婧嵚，罗剑钧，等． 血管内近程放疗联合经动脉化疗栓塞及索拉菲尼治疗肝细胞肝癌合并门脉主干癌栓的疗效分析［J］． 中国临床医学， 2019， 26：46-52．
［11］ 吴林霖，颜志平，张 雯，等． 经动脉灌注化疗联合125I粒子条治疗原发性肝癌合并门脉癌栓的疗效分析［J］． 介入放射学杂志， 2015， 24：776-780．
［12］ 中华人民共和国国家卫生和计划生育委员会．原发性肝癌诊疗规范（2017年版）［J］． 中国实用外科杂志， 2017， 37：705-720．
［13］ Shah ZK， Mckernan MG， Hahn PF， et al. Enhancing and expansile portal vein thrombosis： value in the diagnosis of hepatocellular carcinoma in patients with multiple hepatic lesions［J］. AJR Am J Roentgenol， 2007， 188： 1320-1323.
［14］ Shi J， Lai EC， Li N， et al. Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus［J］. Ann Sura Oncol， 2010， 17： 2073-2080.
［15］ Lencioni R， Llovet JM. Modified RECIST（mRECIST） assessment for hepatocellular carcinoma［J］. Semin Liver Dis， 2010， 30： 52-60.
［16］ Colevas AD，Setser A. The NCI Common Terminology Criteria for Adverse Evernts（CTCAE） v3.0 is the new standard for oncology clinical trials［J］. J Clin Oncol， 2004， 22（14 Suppl）： 6098.
［17］ 杨敏捷，罗剑钧，刘清欣，等． 125I粒子条剂量分布研究［J］．介入放射学杂志， 2015， 24：59-63．
［18］ Huang M， Lin Q， Wang H， et al. Survival benefit of chemoem-bolization plus Iodine125 seed implantation in unresectable hepatitis B- related hepatocellular carcinoma with PVTT： a retrospective matched cohort study［J］. Eur Radiol， 2016， 26： 3428-3436.
［19］ Jia ZZ， Jiang GM， Tian F， et al. A systematic review on the safety and effectiveness of yttrium- 90 radioembolization for hepatocellular carcinoma with portal vein tumor thrombosis［J］. Saudi J Gastroenterol， 2016， 22： 353.
［20］ Yamada K， Izaki K， Sugimoto K， et al. Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma［J］. Int J Radiat Oncol Biol Phys， 2003， 57： 113-119.
［21］ Li XL， Guo WX， Hong XD， et al. Efficacy of the treatment of transarterial chemoembolization combined with radiotherapy for hepatocellular carcinoma with portal vein tumor thrombus： a propensity score analysis［J］. Hepatol Res， 2016， 46： 1088-1098.

相似文献/References:

[1]杨柏帅,施裕新,袁 敏,等.TACE治疗既往有肝功能衰竭史肝癌患者七例[J].介入放射学杂志,2014,(09):805.
　YANG Bo shuai,SHI Yu xin,YUAN Min,et al.TACE treatment for patients with inoperable hepatocellular carcinoma and hepatic failure history： initial experience in seven cases[J].journal interventional radiology,2014,(01):805.
[2]邢桃红,牛焕章,周媛媛,等. TACE联合索拉非尼治疗23例中晚期肝细胞肝癌的护理[J].介入放射学杂志,2014,(05):449.
　XING Tao- hong,NIU Huan- zhang,ZHOU Yuan- yuan,et al. Nursing for patients with advanced hepatocellular carcinoma receiving transcatheter arterial chemoembolization combined with sorafenib： initial experience in 23 cases[J].journal interventional radiology,2014,(01):449.
[3]阿布都外力·吾布力卡斯穆,迪里木拉提·巴吾冬,任伟新. 巴塞罗那肝癌B期患者TACE治疗的预后及生存分析[J].介入放射学杂志,2014,(05):435.
　ABUDUWAILI Obulikasimu,DILMURAT Bawudun,REN Wei- xin.. Transcatheter arterial chemoembolization for the treatment of Barcelona stage B hepatocellular carcinoma： analysis of the prognosis and survival[J].journal interventional radiology,2014,(01):435.
[4]王 龙,张 勇,王亚运,等.125I粒子联合经导管动脉化疗栓塞治疗肝细胞肝癌伴门静脉癌栓临床有效性与安全性meta 分析[J].介入放射学杂志,2018,27(05):419.
　WANG Long,ZHANG Yong,WANG Yayun,et al.125I seed implantation combined with TACE for the treatment of HCC complicated by portal vein tumor thrombus： a meta- analysis of its clinical effectiveness and safety[J].journal interventional radiology,2018,27(01):419.
[5]杨柏帅,施裕新,袁 敏,等.终末期肾衰竭肝癌患者TACE术中应用洛铂治疗3例[J].介入放射学杂志,2016,(05):381.
　YANG Bo- shuai,SHI Yu- xin,YUAN Min,et al.Transcatheter arterial chemoembolization using lobaplatin and lipiodol for the treatment of hepatocellular carcinoma associated with end- stage renal failure： report of three cases[J].journal interventional radiology,2016,(01):381.
[6]许 贇,沈 强,王 能,等.微波消融治疗＞70岁早期肝细胞肝癌患者效果分析[J].介入放射学杂志,2016,(04):332.
　XU Yun,SHEN Qiang,WANG Neng,et al.Effect analysis of microwave ablation therapy for early hepatocellular carcinoma in patients over 70 years old[J].journal interventional radiology,2016,(01):332.
[7]吴志远,丁晓毅,黄 蔚,等.门脉粒子支架联合载药微球栓塞治疗肝癌7例[J].介入放射学杂志,2017,(02):161.
　WU Zhiyuan,DING Xiaoyi,HUANG Wei,et al.Portal 125I seed stent implantation combined with drug-loaded microsphere embolization for the treatment of HCC： initial results in 7 patients[J].journal interventional radiology,2017,(01):161.
[8]王 燕,王茂强,段 峰.索拉非尼治疗中晚期肝癌预后因素分析[J].介入放射学杂志,2017,(03):258.
　WANG Yan,WANG Maoqiang,DUAN Feng.Prognostic factor analysis of moderate- advanced hepatocellular carcinoma treated with sorafenib [J].journal interventional radiology,2017,(01):258.
[9]余天柱,罗剑钧,颜志平.血管内近程放疗与序贯三维适形放疗治疗门静脉主干癌栓的疗效对比 [J].介入放射学杂志,2017,(09):787.
　YU Tianzhu,LUO Jianjun,YAN Zhiping.Endovascular brachytherapy vs. sequential three- dimensional conformal radiotherapy for the treatment of main portal vein tumor thrombus： a comparative study[J].journal interventional radiology,2017,(01):787.
[10]贾中芝,顾晓诚,蒋国民.门静脉癌栓分型对肝细胞性肝癌治疗方法的选择及患者预后的影响 [J].介入放射学杂志,2017,(10):944.
　JIA Zhongzhi,GU Xiaocheng,JIANG Guomin.The application of portal vein tumor thrombus classification in selecting therapeutic method for HCC patients and in estimating the prognosis[J].journal interventional radiology,2017,(01):944.

备注/Memo

备注/Memo:
（收稿日期：2019-10-16）
（本文编辑：俞瑞纲）
更新日期/Last Update: 2021-01-25